NCT00646724

Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Fuzhou General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.

Conditions

• Type 1 Diabetes Mellitus

Interventions

Type	Name	Description
BIOLOGICAL	cotransplantation of islet and mesenchymal stem cell	islet of allograft and MSCs of autograft

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-01-01
• Completion: 2014-01-01
• First posted: 2008-03-28
• Last updated: 2011-06-16

Locations

1 site across 1 country: China